The short trip to San Diego may pay off for owners of private companies in the early stage drug discovery and platform technology if selected to meet March 10 with representatives of the venture group within one of Japan’s largest pharmaceutical companies.
Astellas Venture Management reportedly has hundreds of millions of dollars to invest in companies across several therapeutic areas, including immunology and inflammation, urology, oncology, diabetes mellitus complications, neuroscience ophthalmology, hearing loss, fibrosis, autophagy and regenerative medicine.
The event is being hosted by JLABS, Johnson & Johnson Innovation’s network of life science incubators. Feb. 17 is the deadline to apply for a one-on-one meeting. More information is available at here.